Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals

Vaccine

Volumn 21, Issue 23, 2003, Pages 3186-3199

  Belliard, Guillaume ^a   Romieu, Anthony ^b   Zagury, Jean François ^c   Dali, Hayet ^a   Chaloin, Olivier ^a   Le Grand, Roger ^d   Loret, Erwann ^e   Briand, Jean Paul ^a   Roques, Bernard ^b   Desgranges, Claude ^f   Muller, Sylviane ^a  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b Laboratoire de Pharmacochimie   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e CNRS   (France)

^f INSERM   (France)

Author keywords

B cell epitopes; HIV 1; Tat protein

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MUTANT PROTEIN; TAT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LEUKEMIA CELL LINE; MACACA; MALE; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RHESUS MONKEY; SERUM; T LYMPHOCYTE;

EID: 12444334175     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00233-0     Document Type: Article

References (44)

1. Karn J. Tackling Tat. J. Mol. Biol. 293:1999;235-254.
2. Gatignol A., Jeang K.T. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. Adv. Pharmacol. 48:2000;209-227.
3. Marcello A., Zoppe M., Giacca M. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life. 51:2001;175-181.
4. Liang C., Wainberg M.A. The role of Tat in HIV-1 replication: an activator and/or a suppressor? AIDS Rev. 4:2002;41-49.
5. Westendorp M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H.et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 375:1995;497-500.
6. Frankel A.D., Biancalana S., Hudson D. Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7397-7401.
7. Wrenger S., Hoffmann T., Faust J., Mrestani-Klaus C., Brandt W., Neubert K.et al. The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J. Biol. Chem. 272:1997;30283-30288.
8. Albini A., Ferrini S., Benelli R., Sforzini S., Giunciuglio D., Aluigi M.G.et al. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13153-13158.
9. Boykins R.A., Mahieux R., Shankavaram U.T., Gho Y.S., Lee S.F., Hewlett I.K.et al. A short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J. Immunol. 163:1999;15-20.
10. Wrenger S., Reinhold D., Faust J., Mrestani-Klaus C., Brandt W., Fengler A.et al. Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth. Adv. Exp. Med. Biol. 477:2000;161-165.
11. Betti M., Voltan R., Marchisio M., Mantovani I., Boarini C., Nappi F.et al. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine. 19:2001;3408-3419.
12. Poggi A., Carosio R., Spaggiari G.M., Fortis C., Tambussi G., Dell'Antonio G.et al. NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J. Immunol. 168:2002;95-101.
13. Benelli R., Barbero A., Ferrini S., Scapini P., Cassatella M., Bussolino F.et al. Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. J. Infect. Dis. 182:2000;1643-1651.
14. Rossi C., Balboni P.G., Betti M., Marconi P.C., Bozzini R., Grossi M.P.et al. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients. Gene Ther. 4:1997;1261-1269.
15. Kiernan R.E., Vanhulle C., Schiltz L., Adam E., Xiao H., Maudoux F.et al. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 18:1999;6106-6118.
16. Ott M., Schnolzer M., Garnica J., Fischle W., Emiliani S., Rackwitz H.R.et al. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr. Biol. 9:1999;1489-1492.
17. Krone W.J., Debouck C., Epstein L.G., Heutink P., Meloen R., Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J. Med. Virol. 26:1988;261-270.
18. McPhee D.A., Kemp B.E., Cumming S., Stapleton D., Gust I.D., Doherty R.R. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett. 233:1988;393-396.
19. Tähtinen M., Ranki A., Valle S.L., Ovod V., Krohn K. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Biomed. Pharmacother. 51:1997;480-487.
20. Demirhan I., Chandra A., Hasselmayer O., Biberfeld P., Chandra P. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma. J. Acquir. Immune Defic. Syndr. 22:1999;364-368.
21. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F.et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J. Clin. Virol. 21:2001;81-89.
22. Rodman T.C., Pruslin F.H., To S.E., Winston R. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope. J. Exp. Med. 175:1992;1247-1253.
23. Rodman T.C., To S.E., Hashish H., Manchester K. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7719-7723.
24. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Zauli G., La Placa M. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. Clin. Diagn Lab. Immunol. 3:1996;230-232.
25. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M.et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1:1998;282-292.
26. Rodman T.C., Sullivan J.J., Bai X., Winston R. The human uniqueness of HIV: innate immunity and the viral Tat protein. Hum. Immunol. 60:1999;631-639.
27. Goldstein G., Manson K., Tribbick G., Smith R. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine. 18:2000;2789-2795.
28. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S.et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:1999;643-650.
29. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A.et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 19:2001;2862-2877.
30. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W.et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3515-3519.
31. Li-Weber M., Laur O., Dern K P.H. T cell activation-induced and HIV tat-enhanced CD95 (APO-1/Fas) ligand transcription involves NF-kappaB. Eur. J. Immunol. 30:2000;661-670.
32. Péloponèse J.M., Collette Y., Grégoire C., Bailly C., Campèse D., Meurs E.F.et al. Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents. J. Biol. Chem. 274:1999;11473-11478.
33. Cornille F., Wecker K., Loffet A., Genet R., Roques B. Efficient solid-phase synthesis of Vpr from HIV-1 using low quantities of uniformly 13C-, 15N-labeled amino acids for NMR structural studies. J. Pept. Res. 54:1999;427-435.
34. Neimark J., Briand J.P. Development of a fully automated multichannel peptide synthesizer with integrated TFA cleavage capability. Pept. Res. 6:1993;219-228.
35. Phan Chan Du A., Limal D., Semetey V., Dali H., Jolivet M., Desgranges C.et al. Structural and immunological characterisation of heteroclitic peptide analogues corresponding to the 600-612 region of the HIV envelope gp41 glycoprotein. J. Mol. Biol. 323:2002;503-521.
36. Partidos C.D., Salani B.F., Pizza M., Rappuoli R. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides. Immunol. Lett. 67:1999;209-216.
37. Hendel H., Cho Y.Y., Gauthier N., Rappaport J., Schachter F., Zagury J.F. Contribution of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results. Biomed. Pharmacother. 50:1996;480-487.
38. Rappaport J., Cho Y.Y., Hendel H., Schwartz E.J., Schachter F., Zagury J.F. 32 bp CCR-5 gene deletion and resistance to fast progression in HIV-1 infected heterozygotes. Lancet. 349:1997;922-923.
39. Verrier B., Le Grand R., Ataman-Onal Y., Terrat C., Guillon C., Durand P.Y.et al. Evaluation in Rhesus macaques of Tat and Rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08. DNA Cell Biol. 21:2002;653-658.
40. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102:2001;344-351.
41. Gnann J.W. Jr., Schwimmbeck P.L., Nelson J.A., Truax A.B., Oldstone M.B.A. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J. Infect. Dis. 156:1987;261-267.
42. Smith R.S., Naso R.B., Rosen J., Whalley A., Hom Y.L., Hoey K.et al. Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection. J. Clin. Microbiol. 25:1987;1498-1504.
43. Närvänen A., Korkolainen M., Suni J., Korpela J., Kontio S., Partanen P.et al. Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection. J. Med. Virol. 26:1988;111-118.
44. Cafaro A., Caputo A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M.et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol. 29:2000;193-208.